SCHEMBL6414183

SCHEMBL6414183

C(=N/Nc1nc2nonc2nc1NCc1ccccc1)\c1cc2ccccc2o1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.40
LMNA P02545 5/20 0.40
KMT2A Q03164 4/20 0.40
HTT P42858 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
MAPK1 P28482 3/20 0.40
KDM4E B2RXH2 3/20 0.40
MEN1 O00255 2/20 0.40
BLM P54132 1/20 0.40
BIRC5 O15392 1/20 0.37
ALDH1A1 P00352 2/20 0.36
TP53 P04637 1/20 0.36
HPGD P15428 1/20 0.36
NPSR1 Q6W5P4 5/20 0.35
TDP1 Q9NUW8 3/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
CYP2A6 P11509 1/20 0.35
MAOB P27338 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6414195 1.00 MAPT (0.40) MAPTLMNAKMT2AHTTSMN1; SMN2
SCHEMBL6503765 0.84 BIRC5 (0.42) MAPTKMT2AHTTSMN1; SMN2KDM4E
SCHEMBL6416985 0.81 MAPT (0.51) MAPTLMNAKMT2AHTTSMN1; SMN2
SCHEMBL6416975 0.81 MAPT (0.51) MAPTLMNAKMT2AHTTSMN1; SMN2
SCHEMBL6510185 0.81 BIRC5 (0.50) MAPTLMNAKMT2AHTTSMN1; SMN2
SCHEMBL6435778 0.78 MAPT (0.47) MAPTLMNAKMT2AHTTSMN1; SMN2
SCHEMBL6435783 0.78 MAPT (0.47) MAPTLMNAKMT2AHTTSMN1; SMN2
SCHEMBL6418400 0.78 CA1 (0.49) MAPTLMNAKMT2AHTTSMN1; SMN2
SCHEMBL6414142 0.77 MAPT (0.43) MAPTLMNAKMT2AHTTSMN1; SMN2
SCHEMBL6414665 0.77 DDX3X (0.53) MAPTLMNAKMT2AHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MAPT 4420/4885LMNA 4510/4885KMT2A 3640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.